Sol-Gel Technologies (SLGL) Operating Leases (2019 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Operating Leases of $377000.0 for Q1 2026, down 49.46% year-over-year from $746000.0 in Q1 2025, and down 23.99% quarter-over-quarter from $496000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Operating Leases (2019 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Operating Leases for 8 consecutive years, with $377000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 49.46% year-over-year to $377000.0; the TTM figure through Mar 2026 stood at $377000.0 (down 49.46% YoY), while the FY2025 annual figure was $496000.0, down 43.51% from the prior year.
- Operating Leases declined to $377000.0 in Q1 2026 per SLGL's latest filing, from $496000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $1.2 million in Q3 2023 and bottomed at $30000.0 in Q1 2023.
- Historically, Operating Leases has averaged $627764.7 across 5 years, with a median of $600000.0 in 2022.
- Annual changes were most pronounced in 2023 — Operating Leases sank 95.0% — and 2024, when it jumped 3676.67%.
- Sol-Gel Technologies' Operating Leases stood at $54000.0 in 2022, then soared by 2133.33% to $1.2 million in 2023, then dropped by 27.2% to $878000.0 in 2024, then slumped by 43.51% to $496000.0 in 2025, then declined by 23.99% to $377000.0 in 2026.
- Business Quant data shows SLGL's Operating Leases at $377000.0 in Q1 2026, $496000.0 in Q4 2025, and $592000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 377,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Sep 30, 2025 | 592,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 746,000.00 |
| Dec 31, 2024 | 878,000.00 |
| Sep 30, 2024 | 922,000.00 |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.13 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 1.22 Mn |
| Jun 30, 2023 | 136,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 193,000.00 |
| Jun 30, 2022 | 369,000.00 |
| Mar 31, 2022 | 600,000.00 |
| Dec 31, 2021 | 810,000.00 |
| Sep 30, 2021 | 803,000.00 |
| Jun 30, 2021 | 958,000.00 |